Asking for Preferences

Reading File

Finding Sources

Searching PubMed

"pulmonary embolism"[MeSH Terms] AND "diagnosis"[MeSH Terms]

Searching Images

pulmonary embolism CT pulmonary angiography saddle embolus

This diagnostic axial CT angiography (CTA) scan of the chest reveals a classic saddle pulmonary embolism. The primary visual finding is a large, low-attenuation filling defect centrally located at the bifurcation of the main pulmonary artery. This thrombus straddles the carina and extends into both the right and left pulmonary arteries. Two red arrows indicate the specific sites where the hypodense embolus obstructs the contrast-enhanced pulmonary vasculature. The surrounding mediastinal structures, including the ascending aorta and the superior vena cava, are visible and show normal contrast enhancement. This imaging modality is the gold standard for diagnosing acute pulmonary embolism, and the 'saddle' configuration demonstrated here indicates a massive or submassive embolic event with high clinical significance for hemodynamic instability.

This diagnostic image is an axial cut from a CT Pulmonary Angiography (CTPA) demonstrating extensive pulmonary embolism. The primary visual finding is a large, low-attenuation filling defect appearing as a 'saddle embolus' at the bifurcation of the main pulmonary artery, extending into both the right and left main pulmonary arteries (indicated by red arrows). The central filling defects are characterized by absent or significantly reduced contrast enhancement within the vessel lumens, which are otherwise surrounded by hyperdense contrast material. Additional thromboembolic material is visible in the lobar and segmental branches bilaterally. The main pulmonary artery shows evidence of distension secondary to the large obstructive clot burden. This image serves as a classic clinical example of acute, high-burden pulmonary embolism in a patient with risk factors such as prolonged immobility, illustrating the critical role of CTPA in diagnosing life-threatening vascular obstructions.

**Imaging Modality:** Contrast-enhanced Computed Tomography (CT) of the chest, specifically a CT Pulmonary Angiography (CTPA) protocol. **Anatomical Region:** Axial section of the thorax at the level of the pulmonary artery bifurcation. **Observed Pathology:** Large, bilateral pulmonary embolism. A prominent "saddle" embolus is visible, characterized by low-attenuation (hypodense) filling defects within the lumen of the main pulmonary artery, extending into both the right and left main pulmonary arteries. **Characteristic Visual Features:** * **Filling Defects:** Central non-opacified areas surrounded by radiopaque contrast media, creating the classic "Polo Mint" sign in cross-section or "railway track" sign in longitudinal views. * **Vascular Anatomy:** The pulmonary trunk appears dilated. * **Surrounding Structures:** The ascending and descending aorta, superior vena cava, and vertebral body are visible and unremarkable in this single slice. Metal streak artifacts are present anteriorly from sternal wires, suggesting prior cardiac surgery. **Key Diagnostic Features:** The presence of a large, centrally located thrombus straddling the bifurcation of the pulmonary trunk (saddle embolus) is the pathognomonic finding for acute major pulmonary embolism.

This diagnostic image is an axial contrast-enhanced CT Pulmonary Angiography (CTPA) of the chest. It demonstrates significant bilateral acute pulmonary emboli within the pulmonary arterial tree. Key findings include prominent, low-attenuation filling defects (darker regions) contrasted against the bright, opacified blood in the pulmonary arteries. Specifically, white arrows highlight large clots obstructing the main right and left pulmonary arteries, consistent with a saddle embolus configuration. Smaller peripheral filling defects are also visible in the branching segments of the arterial tree. Other visible thoracic structures include the ascending and descending aorta, the heart, and the superior vena cava, which show normal contrast enhancement. The image serves as a clinical illustration of massive pulmonary embolism causing significant vascular obstruction, often associated with hemodynamic instability and right ventricular strain in an acute clinical setting.

Reading File

Finding Sources

Reading File

I now have comprehensive information. Let me compile the full overview.

Pulmonary Embolism (PE) - Comprehensive Overview

Definition & Epidemiology

Pulmonary embolism is the obstruction of one or more pulmonary arteries, almost always by thrombus originating from the deep veins of the lower extremities (>95% of cases). It is the third most frequent cardiovascular disease, with an annual incidence of 75-270 cases per 100,000 inhabitants. Approximately one-third of patients die within the first hours of presentation, often because the diagnosis was missed. Anticoagulation reduces mortality substantially. In ~1% of cases, incomplete resolution leads to chronic thromboembolic pulmonary hypertension (CTEPH). - Fuster and Hurst's The Heart, 15th Ed.

Pathophysiology (Virchow's Triad)

PE arises from venous thrombosis driven by:

Stasis (immobility, prolonged bed rest, long-haul travel)
Vessel wall injury (surgery, trauma, indwelling catheters)
Hypercoagulability (malignancy, oral contraceptives, pregnancy, Factor V Leiden, protein C/S deficiency, antiphospholipid syndrome)

Most thrombi originate in valve pockets of the calf veins, then propagate proximally before embolizing. VTE is classified as provoked (reversible risk factor within 3 months) or unprovoked (no identifiable trigger). - Fuster and Hurst's The Heart, 15th Ed.

Two primary pathophysiologic consequences:

Respiratory compromise - the obstructed lung segment is ventilated but not perfused (V/Q mismatch), creating dead space and hypoxemia
Hemodynamic compromise - increased pulmonary vascular resistance leads to acute RV pressure overload, RV failure, and reduced LV preload; sudden death results from blockage of pulmonary outflow

Large emboli lodge as saddle emboli at the pulmonary artery bifurcation; smaller emboli travel peripherally and may cause hemorrhage or infarction (~10% of all emboli infarct; ~75% affect the lower lobes). - Robbins & Cotran Pathologic Basis of Disease

Clinical Presentation

Symptoms

Dyspnea (most common; 75-80% of patients, but absent in ~25%)
Chest pain (second most common; pleuritic in only ~20%)
Cough, hemoptysis (when pulmonary infarction occurs)
Palpitations, fatigue, vague malaise
Unexplained unilateral leg swelling (DVT source; <30% of PE patients)
Syncope (<5% of presentations, but raises suspicion when unexplained)

A patient with fever >38.6°C or productive sputum cough is more likely to have pneumonia than PE.

Signs

Tachycardia (most common ECG finding)
Tachypnea, hypoxia
Hypotension / cardiogenic shock (high-risk/massive PE)
Neck vein distension, RV S3 (overt right heart failure)
Leg swelling / tenderness

"Virtually any ED presentation with dyspnea, chest pain, palpitations, or syncope could represent PE." - Rosen's Emergency Medicine

ECG Findings

ECG is more useful for excluding alternative diagnoses than confirming PE. When PE causes ECG changes, they reflect acute pulmonary hypertension and RV dysfunction:

Tachycardia (most common)
S1Q3T3 pattern (McGinn-White sign)
Symmetric T-wave inversions in V1-V4
Incomplete or complete right bundle branch block

Any one of these roughly doubles the probability of PE in a symptomatic patient, though all are nonspecific.

Diagnosis

Step 1 - Pretest Probability

The Wells Score is the most validated clinical decision tool. It incorporates 7 variables. A simplified version assigns 1 point each and is validated for outpatient use. The Revised Geneva Score (8 variables, no imaging/gas exchange required) is an equally validated alternative. The "test threshold" for pursuing objective testing in PE is approximately 1.5-2% probability. - Fuster and Hurst's The Heart, 15th Ed.

Wells Score Variable	Points
Clinical signs/symptoms of DVT	3
PE more likely than alternative diagnosis	3
Heart rate >100 bpm	1.5
Immobilization/surgery in last 4 weeks	1.5
Prior DVT or PE	1.5
Hemoptysis	1
Active malignancy	1

Score interpretation: Low (<2), Moderate (2-6), High (>6)

Step 2 - D-Dimer

A negative, highly sensitive ELISA D-dimer (below assay-specific cutoff) excludes PE in low- to moderate-probability patients with >95% sensitivity and negative predictive value. D-dimer is not useful in:

High pretest probability patients
Hospitalized/postoperative patients (many comorbidities elevate baseline levels)
Patients >80 years (specificity drops to ~10%)
Second/third trimester pregnancy

An age-adjusted D-dimer cutoff (age × 10 mcg/L in patients >50 years) increases specificity without compromising safety.

Step 3 - Imaging

CT Pulmonary Angiography (CTPA) is the gold standard - it identifies filling defects in the pulmonary vasculature and can also show RV dilation, contrast reflux into the IVC, and right heart strain.

Saddle pulmonary embolism on CTPA - large filling defect straddling the bifurcation of the main pulmonary artery

Classic saddle embolus on CTPA: low-attenuation filling defect at the pulmonary artery bifurcation extending into both right and left pulmonary arteries.

V/Q Scanning - indicated when CTPA is contraindicated (contrast allergy, renal insufficiency, pregnancy). Normal V/Q excludes PE; high-probability V/Q (segmental or larger mismatch) confirms it. Nondiagnostic in up to 70% of cases. The PIOPED study showed high-probability scans have 97% specificity but only 41% sensitivity.

Echocardiography - useful in hemodynamically unstable patients when imaging is not feasible. RV dilation, hypokinesis, and paradoxical septal motion ("D-sign") indicate RV strain.

Venous Compression Ultrasonography - documents DVT; a positive result in a high-suspicion patient can direct treatment without CTPA.

Risk Stratification

Once PE is confirmed, risk stratification guides treatment intensity:

Category	Old Term	Definition
High-risk	Massive	SBP ≤90 mmHg for ≥15 min OR cardiogenic shock
Intermediate-risk	Submassive	Normotensive + RV dysfunction (echo or CTPA) and/or elevated troponin/BNP
Low-risk	-	No hemodynamic compromise, no RV strain, low sPESI score

Mortality: ~70% with cardiopulmonary arrest, ~30% with cardiogenic shock, <5% with low-risk PE. - Fuster and Hurst's The Heart, 15th Ed.

Management

Anticoagulation (all PE categories)

Start anticoagulation immediately when suspicion is high and bleeding risk is acceptable - even before diagnosis is confirmed. This is the one intervention proven to reduce PE mortality.

DOACs (first-line in most patients):

Rivaroxaban or apixaban - can be started directly without parenteral bridging (after initial loading doses for 1-3 weeks)
Dabigatran or edoxaban - require 5-10 days of parenteral anticoagulation first
DOACs are noninferior to LMWH/warfarin for efficacy and have significantly less major bleeding (especially intracranial hemorrhage)

LMWH - preferred parental agent; advantages over UFH include no monitoring, earlier ambulation, and home therapy in select patients.

Unfractionated Heparin (UFH) - preferred when rapid reversibility is needed (planned procedures, high bleeding risk, renal failure).

Warfarin (VKA) - now rarely used. Still indicated in breastfeeding, super-morbid obesity, or mechanical heart valves. Must overlap with heparin for ≥5 days (avoids early prothrombotic protein C/S depletion).

Duration of Anticoagulation

Provoked PE (reversible trigger): 3 months minimum
Unprovoked PE: at least 3-6 months; consider indefinite based on recurrence risk and bleeding profile
Cancer-associated PE: LMWH or DOAC (edoxaban/rivaroxaban) indefinitely while cancer active

Thrombolysis (High-Risk/Massive PE)

Systemic thrombolysis (alteplase IV) is indicated for hemodynamically unstable PE (persistent hypotension despite fluids, or cardiogenic shock). Contraindicated in recent surgery, stroke, or high bleeding risk.

Catheter-directed thrombolysis (CDT) and mechanical thrombectomy are emerging options for intermediate/high-risk PE with contraindications to systemic lysis. A recent 2025 meta-analysis (PMID: 40269600) compared mechanical thrombectomy vs. CDT.

Surgical embolectomy - reserved for massive PE when thrombolysis fails or is contraindicated. Provides direct extraction from the main pulmonary arteries.

ECMO - considered for refractory cardiogenic shock as a bridge to definitive therapy.

IVC Filters

Indicated when anticoagulation is absolutely contraindicated AND the patient has proven PE or DVT. Retrievable filters are preferred. No mortality benefit has been demonstrated when added to anticoagulation in stable patients. - Fuster and Hurst's The Heart, 15th Ed.

PE Response Team (PERT)

A multidisciplinary team (emergency medicine, pulmonology, cardiology, cardiac surgery, interventional radiology) that convenes for intermediate- and high-risk PE. PERT implementation is associated with more aggressive use of advanced therapies and a trend toward reduced mortality.

Special Populations

Pregnancy: Risk is 5x higher than non-pregnant age-matched women. Diagnosis is complicated by physiological overlap (dyspnea, edema). The pregnancy-adapted YEARS algorithm can safely exclude PE in many women. CTPA carries higher maternal breast radiation; V/Q carries lower fetal dose. LMWH is the anticoagulant of choice throughout pregnancy (warfarin is teratogenic in weeks 6-12; DOACs have insufficient pregnancy safety data). - Murray & Nadel's Textbook of Respiratory Medicine

Complications

CTEPH (Chronic Thromboembolic Pulmonary Hypertension): Occurs in ~1-3.8% after first PE, ~13% after recurrent VTE. Progressive exertional dyspnea, RV failure. Diagnosed by V/Q mismatch + right heart catheterization. Treated with pulmonary endarterectomy (definitive), riociguat, or balloon pulmonary angioplasty.
Post-PE syndrome: Persistent dyspnea and functional limitation after PE, even without CTEPH.
Recurrent VTE: Risk is highest in unprovoked PE and cancer-associated VTE.

Summary Algorithm

Assess pretest probability (Wells or Geneva score)
Low/moderate probability → D-dimer: if negative, PE excluded; if positive → CTPA
High probability → CTPA directly (skip D-dimer)
Hemodynamically unstable → Bedside echo; if RV dysfunction confirmed → systemic thrombolysis or embolectomy without delay
Confirmed PE → Risk-stratify → anticoagulate; escalate therapy if high/intermediate-risk

Recent evidence note: A 2025 meta-analysis (PMID: 40269600, Catheter Cardiovasc Interv) compared mechanical thrombectomy versus catheter-directed thrombolysis in PE, with results supporting growing use of catheter-based approaches for intermediate/high-risk cases. A 2025 meta-analysis (PMID: 40412084) evaluated AI-based deep learning models for PE detection on CTPA, finding high sensitivity but variable performance. Neither fundamentally changes current guideline management but they may influence future practice.

Create a comparison poster of DOAC vs. warfarin for PE anticoagulation

Generating Image

A clean, professional medical comparison poster titled "DOAC vs. Warfarin for PE Anticoagulation" with two columns side by side. Left column in deep blue labeled "DOACs (Direct Oral Anticoagulants)" listing: Agents: Rivaroxaban, Apixaban, Dabigatran, Edoxaban. Fixed dosing, no routine monitoring. Rapid onset (1-4 hours). Most can start without parenteral bridging (rivaroxaban, apixaban). Noninferior efficacy vs warfarin. Significantly less intracranial bleeding. Predictable pharmacokinetics. Preferred in renal function >30 mL/min. Limited reversal agents (andexanet alfa for Xa inhibitors, idarucizumab for dabigatran). Avoid in pregnancy and breastfeeding. Cost: higher. Right column in deep red labeled "Warfarin (Vitamin K Antagonist)" listing: Variable dosing, requires INR monitoring (target 2.0-3.0). Slow onset - requires 5-10 day heparin bridge. Many drug and food interactions. Teratogenic (weeks 6-12) - avoid in pregnancy. Reversal: Vitamin K, FFP, PCC. Lower cost, widely available. Preferred in: mechanical heart valves, antiphospholipid syndrome, severe renal failure, pregnancy. At the bottom, a highlighted box: "DOACs are now first-line for most PE patients per current guidelines." Include a small molecular/blood clot icon at the top. Medical infographic style, white background, clear typography.

DOAC vs. Warfarin for PE Anticoagulation Comparison Poster

Here's your comparison poster. Key takeaways captured in it:

DOACs win on:

Convenience (fixed dosing, no INR checks)
Safety (less intracranial/major bleeding)
Speed (rapid onset, most skip the heparin bridge)
Predictability

Warfarin still preferred when:

Mechanical heart valves (DOACs contraindicated)
Antiphospholipid antibody syndrome (trials showed DOACs inferior)
Severe renal failure (CrCl <15-30 mL/min depending on agent)
Pregnancy/breastfeeding (LMWH is actually the go-to here, not warfarin either)
Cost is a hard barrier

The bottom line matches current guidelines from ESC, AHA, and ACCP: DOACs are first-line for most patients with PE, with warfarin reserved for specific clinical scenarios.

This is a shared conversation. Sign in to Orris to start your own chat.